Table 3.

Clinical individual patient and immunohistochemical melanoma metastases characterization

Sample ID	Patient ID	Response BOR	OS mo	Obs	Biopsy time point	Type of immunotherapy	Pattern of T cell infiltration	CD20 + cells B cells	CD163 + cells Mø	Ki67 + cells proliferation	Tissue type	Processed for RNA-seq and MBD-seq
High clinical benefit
MEL1	PAT1	PR	46		Before	Ipi	B	Yes	Yes	No	LN	Yes
MEL2	PAT2	PR	37+	This sample is a regression lesion	After	TriMixIpi	E	Yes	Yes	Yes	Sc nodule	Yes
MEL3	PAT3	CR	39+		Before	TriMixIpi	C	Yes	Yes	Yes	LN	Yes
MEL4							C	Yes	Yes	Yes	LN	No
MEL5	PAT4	CR	43+		Before	TriMixIpi	C	Yes	Yes	Yes	LN	Yes
MEL6	PAT5	CR	29+		Before	TriMixIpi	B	No	Yes	Yes	Skin MTS	Yes
MEL7							C	No	Yes	Yes	LN	No
No clinical benefit
MEL14	PAT12	PD	14		After	TriMixIpi	C	No	Yes	Yes	Small intestine	Yes
MEL15	PAT13	PD	3		Before	TriMixIpi	B	Yes	Yes	Yes	LN	Yes
MEL16	PAT14	PD	13		After	TriMixIpi	C	Yes	Yes	Yes	LN	Yes
MEL17	PAT15	PD	14		After	TriMixIpi	A/B	No	Yes	Yes	Brain	Yes
MEL18	PAT16	PD	8	First line was Ipi but MTS was removed after receiving also TriMixIpi	After	Ipi	C	No	Yes	Yes	Liver	Yes
MEL19	PAT17	PD	6		Before	Ipi	NE	NE	Yes	NE	Adrenal gland	Yes
MEL20	PAT18	PD	9		Before	TriMixIpi	B	No	Yes	No	Sc nodule	Yes
MEL21	PAT19	PD	16		Before	Ipi	Heterogenous A and C	No	Yes	Yes	Small intestine	No
MEL22	PAT20	PD	10		Before	Ipi	Heterogenous E and C	No	Yes	Yes	Lung	No
MEL23	PAT21	PD	26	First line was Ipi but MTS was removed after receiving Ipi, TriMixIpi and Ipi reinduction	After	Ipi	D	No	Yes	Yes	Sc nodule	No
MEL24	PAT22	PD	10		After	TriMixIpi	E but weak infiltration	No	Yes	Yes	Sc nodule	No
MEL25	PAT23	PD	10		Before	TriMixIpi	NE	NE	NE	NE	LN	No
MEL26	PAT24	PD	35	Experienced DC vaccination, Ipi, Ipi reinduction, DC vaccination combined with Ipi, and TIL therapy	After	Ipi	C	Yes	Yes	Yes	Sc nodule	No